Hansen Medical Announces Appointment of Chris Lowe as Interim CEO; Bruce Barclay to Depart the Company

MOUNTAIN VIEW, CA--(Marketwired - Feb 10, 2014) -  Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that current Board member Chris Lowe has been appointed Interim Chief Executive Officer effective yesterday. Mr. Lowe succeeds Bruce J. Barclay, President and CEO since 2010. The Board of Directors has retained Russell Reynolds Associates to conduct a search for a new CEO.

"We thank Bruce for his many contributions to Hansen Medical. Bruce's leadership has helped position the company as a leader in intravascular robotics," stated Mike Eagle, the Chairman of the Board of Directors. "The Board looks forward to supporting Chris and the management team through this transition."

Mr. Lowe is a veteran of the health care industry who joined Hansen Medical as a Director in September 2006. Mr. Lowe's industry roles have included serving as Chief Financial Officer and Chief Business Officer of Anthera Pharmaceuticals (NASDAQ: ANTH), Chief Financial Officer of Asthmatx, a medical device company acquired by Boston Scientific and Chief Accounting Officer at Peninsula Pharmaceuticals, acquired by Johnson & Johnson. Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary's University, Texas.

Investor Contacts:
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
650.404.5800

Westwicke Partners, LLC.
Mark Klausner
443.213.0501
Email Contact

Mike Piccinino, CFA
443.213.0509
Email Contact